完整分析组包括LHQW胶囊组410名患者和安慰剂组405名患者。在完整分析组中,LHQW显著缩短了主要终点的时间(4.0 vs. 6.7天,风险比:1.63,95%置信区间:1.39-1.90)。LHQW胶囊缩短了持续临床改善或鼻塞、流感症状(2.8 vs. 3.7天)、喉咙痛(2.0 vs. 2.6天)、咳嗽(3.2 vs. 4.9天)、发热感(1.0 vs. 1.3天)、低能量或疲劳感(1.3 vs. 1.9天)以及肌肉疼痛(1.5 vs. 2.0天)的中位时间。在两组之间,持续临床改善或呼吸急促、头痛以及寒战或发冷的中位时间没有显著差异。两组的安全性相当,未报告严重不良事件。
结论
LHQW胶囊可中轻度症状缓解,促进轻度至中度COVID-19的恢复,并且耐受性良好。
实验分组没有按照中医理论
受试者入选的条件是18-70岁之间,轻中度新冠患者,核酸或抗原检测阳性,至少有三个症状:
Briefly, eligible patients were aged 18-70 years, had mild-to-moderate COVID-19 (according World Health Organization), tested positive to either rapid antigen test (RAT) or nucleic acid amplification test (NAAT), had an interval between symptom onset and screening of within 4 days, and had at least three major symptoms (stuffy or runny nose, sore throat, cough, shortness of breath, low energy or tiredness, myalgia, headache, chills or shivering, feeling hot or feverish) occurring within 12 hours prior to screening.
Both groups received standard-of-care consisting of antipyretics, analgesic drugs, nutrition supplementation and fluid replacement. Acetaminophen, the non-steroidal anti-inflammatory drug, could be applied for ameliorating fever if the temperature reached 38.5 degrees or higher.
给了什么解热镇痛的药物,语焉不详。补充材料有一段说明[6]:
Symptomatic treatment such as antipyretic analgesia, adequate nutrition and appropriate rehydration in patients with mild COVID-19 were allowed according to the study protocol. Antipyretic and analgesic acetaminophen could be given as symptomatic treatment when the body temperature exceeded 38.5°C.